September/October 2012 Vol 5, No 6

Clinical

National Burden of Preventable Adverse Drug Events Associated with Inpatient Injectable Medications: Healthcare and Medical Professional Liability Costs
Betsy J. Lahue, MPH
; Bruce S. Pyenson, FSA, MAAA
; Kosuke Iwasaki, FIAJ, MAAA
; Helen E. Blumen, MD, MBA
; Susan Forray, FCAS, MAAA
; Jeffrey M. Rothschild, MD, MPH
Stakeholder Perspective by Jaan Sidorov, MD, MHSA
Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study
Barb Lennert, RN, BSN, MAOM
; Wendy Bibeau, PhD
; Eileen Farrelly, MPH
; Patricia Sacco, MPH, RPh
; Tessa Schoor, MD
Stakeholder Perspective by Gary M. Owens, MD

Business

"Hidden” Value: How Indirect Benefits of Health Information Exchange Further Promote Sustainability
Albert Tzeel, MD, MHSA, FACPE
; Victor Lawnicki, PhD
; Kim R. Pemble, MS
Stakeholder Perspective by Jack E. Fincham, PhD, RPh
Medical Care Costs and Hospitalization in Patients with Bipolar Disorder Treated with Atypical Antipsychotics
Joette Gdovin Bergeson, PhD, MPA
; Iftekhar Kalsekar, PhD
; Yonghua Jing, PhD
; Min You, MS
; Robert A. Forbes, PhD
; Tony Hebden, PhD
Stakeholder Perspective by Jeff Januska, PharmD

Editorial

Hardworking P&T Committees
David B. Nash, MD, MBA

Drug Utilization Trends

Payer Drug and Molecular Testing Utilization Policies
Charles Bankhead, Medical Writer

Industry Trends

Cost Management through Care Management, Part 2: The Importance of Managing Specialty Drug Utilization in the Medical Benefit
Michael T. Einodshofer, RPh, MBA
; Lars N. Duren, BCNSP, PharmD

Multiple Sclerosis Update

Multiple Sclerosis: Patient Characteristics and Cost Concerns
Charles Bankhead, Medical Writer